Fred Ehrsam, co-founder of Coinbase, has revealed a new brain-interface device through his neuroscience startup Nudge, signaling a deeper shift away from crypto and toward neurotechnology. The company’s first product, called Nudge Zero, is described as a non-invasive ultrasound neuromodulation device. In practical terms, that means it uses ultrasound waves to influence brain activity without surgery and, according to the report, without causing permanent changes or damage to brain tissue.
From Crypto Pioneer to Neurotechnology Builder
Ehrsam is best known in the digital asset world for helping launch Coinbase with Brian Armstrong in a two-bedroom apartment thirteen years ago. Since then, both founders have become billionaires, but Ehrsam’s recent trajectory shows an increasingly visible move into neuroscience. In 2024, he launched Nudge, a company focused on building technology that interfaces directly with the brain.
Before Nudge, Ehrsam also helped establish one of crypto’s most influential investment firms. In 2018, he and former Sequoia partner Matt Huang co-founded Paradigm, a crypto-focused venture capital firm. The article notes that Paradigm manages three funds, with the latest closing at $850 million last June. Ehrsam stepped down from his role as managing partner in 2023, though he remained at the firm as a general partner.
That background matters because it places Nudge Zero in a broader context: this is not a casual side project from a well-known crypto executive. It is the latest step in a deliberate transition by a founder who has already built and funded major companies in digital finance and venture investing.
What Nudge Zero Is Designed to Do
Nudge Zero is built around ultrasound neuromodulation, a field that aims to alter or influence brain activity using ultrasound rather than implants or more invasive interventions. The source material explains that the device affects cell membranes in the brain through ultrasound waves. While the phrase may sound highly technical, the practical significance is easier to understand: it is an attempt to interact with the brain from outside the body, potentially opening paths for treatment without requiring surgery.
The potential use cases for devices like Nudge Zero generally fall into two overlapping categories: medical and therapeutic. On the medical side, examples mentioned include neurological conditions such as epilepsy and pain management. On the therapeutic side, the technology could eventually be applied to less acute issues, including depression or broader forms of mental well-being support.
According to Ehrsam, Nudge will begin with the more immediate medical path. He said the company plans to use the device in the coming months in an effort to address acute medical conditions. That initial focus suggests a cautious product rollout centered on serious health applications before any broader consumer ambitions are pursued.
A Longer-Term Vision Beyond Clinical Care
Although the first phase is medically oriented, Ehrsam’s longer-term vision is much broader. He said the eventual goal is to create a miniaturized version of the technology, something closer to a pair of headphones, that could be used by healthy individuals to improve mood, cognition, and daily life. That framing positions Nudge not only as a medical technology company but also as a possible future player in the emerging market for neurotechnology aimed at performance, mental wellness, and everyday human enhancement.
This dual ambition is notable. Many early-stage neurotechnology companies begin with clinical applications, where the need is clearer and the social value is easier to define. But the reference to a headphone-like device for healthy users points to a more expansive future in which brain-interface tools might be incorporated into mainstream consumer technology—if the underlying science, regulation, and safety profile evolve in that direction.
Ehrsam’s Stated Mission
Nudge’s mission, as described in the report, is to “develop the best technology for interfacing with the brain to improve people’s lives.” Ehrsam framed the company’s purpose in even broader philosophical terms, saying that improving the human experience is the most important thing technology should work on, and that building technologies that interface with the brain is the most direct way to pursue that objective.
That statement helps explain why his current focus appears to be shifting beyond crypto. While digital assets and blockchain infrastructure remain central to his public profile, the launch of Nudge Zero indicates that neuroscience may now be the domain where he sees the greatest long-term opportunity for impact.
The Profile Behind the Launch
The report states that Ehrsam is 36 years old and has a net worth of approximately $2.1 billion, according to Forbes. His financial success from Coinbase and subsequent work at Paradigm has given him the ability to pursue highly ambitious frontier technologies—an increasingly common pattern among entrepreneurs who made their fortunes in software, finance, or crypto before moving into fields such as biotech, defense, artificial intelligence, and brain science.
In Ehrsam’s case, the move into neuroscience appears especially significant because it is being done through a dedicated company with a clearly articulated mission and a first product already introduced. Nudge Zero may still be at an early stage, but its unveiling marks a concrete milestone rather than a speculative concept announcement.
Why the Announcement Matters
For the crypto industry, the launch is another example of how prominent founders are extending their influence far beyond blockchain markets. Ehrsam’s career now connects three distinct areas: a major crypto exchange, a leading crypto investment firm, and a startup focused on brain-interface technology. That arc reflects a broader trend in which entrepreneurial talent and capital generated in crypto are increasingly flowing into adjacent deep-tech sectors.
For the neurotechnology space, Nudge Zero adds visibility at a time when interest in non-invasive brain-interfacing tools continues to grow. The emphasis on ultrasound-based modulation is particularly notable because it suggests an attempt to influence brain function without relying on implants, which are often more complex from both a medical and adoption standpoint.
Much remains to be seen about how quickly Nudge’s technology can move from early medical use cases to broader therapeutic or consumer applications. Still, the unveiling of Nudge Zero establishes Ehrsam’s next chapter in unmistakable terms: after helping build one of crypto’s defining companies, he is now betting that the next major frontier lies in the brain.